SecBot SecBot
PRESS-RELEASE ·Filed Jun 2, 2026

KURA

Kura Oncology, Inc.
BULLISH
Impact 6/10
Horizonweeks Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Watch for KOMET-017 Phase 3 data readouts and potential FDA filing for the combination regimen as the next catalysts.

DirectionBullish
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$8.97
T+0 close · Jun 2, 2026 · via day close
Latest settled
+45.60%
T+60 · $13.06
Vs SPY
+44.48%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 2 $8.97entry
  2. T+1 · 6mo ago −3.51%α −2.82% · $8.66
  3. T+5 · 5mo ago −1.78%α +1.18% · $8.81
  4. T+20 · 5mo ago +20.18%α +21.74% · $10.78
  5. T+60 · 3mo ago +45.60%α +44.48% · $13.06
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Kura Oncology announced publication in Blood of updated Phase 1a/b KOMET-007 data for ziftomenib + venetoclax + azacitidine in relapsed/refractory NPM1-mutated AML. In venetoclax-naïve patients at the 600 mg dose, the combination showed a 70% CRc rate, 75% central MRD negativity, and median OS not reached after 10.7 months follow-up.

Key Facts

  • 87% ORR and 70% CRc in venetoclax-naïve R/R NPM1-m AML patients at 600 mg ziftomenib dose
  • 75% central MRD negativity (<0.01% threshold) in CRc responders with no prior venetoclax
  • Median CRc duration 9.2 months; median OS not reached after 10.7 months follow-up in venetoclax-naïve
  • 48% ORR and 24% CRc in venetoclax-experienced patients at 600 mg dose
  • Low rates of differentiation syndrome (3%) and QTc prolongation (1 case) observed
  • Ziftomenib (KOMZIFTI) is FDA-approved as monotherapy for R/R NPM1-m AML
  • KOMET-017 Phase 3 trials in newly diagnosed NPM1-m and KMT2A-r AML are ongoing

Financial Impact

No financial figures provided in press release; clinical data supports potential label expansion into combination therapy, which could expand addressable market beyond monotherapy

pipeline valueaddressable market

Risk Factors

  • Combination regimen is investigational and not yet FDA-approved
  • Differentiation syndrome boxed warning remains a safety concern
  • Competition from other menin inhibitors (e.g., Syndax's revumenib) could limit market share
  • Phase 3 trials may fail to replicate Phase 1b results

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3305195

Track record

29 reports on KURA

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +52.28% at T+60 after the Jun 3, 2026 report. 9 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Buy Bullish 5/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  2. Nov 16, 2026today 144 Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  4. Nov 10, 20266d ago S-3ASR Neutral 4/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
  5. Nov 10, 20266d ago Press Release Neutral 5/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
  6. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $7.61 Now $7.09 −6.83% settles Feb 2
  7. Sep 29, 20266w ago Insider Cluster Bearish 5/10 Entry $10.71 Now $7.09 +33.80% settles Dec 24
  8. Sep 29, 20266w ago Press Release Bullish 6/10 Entry $10.81 Now $7.09 −34.38% settles Dec 23
  9. Sep 9, 20269w ago 8-K Bullish 6/10 Entry $12.09 Now $7.09 −41.36% settles Dec 3
  10. Sep 8, 20269w ago 8-K Neutral 2/10 Entry $12.52 Now $7.09 −43.37% settles Dec 2
Showing 10 of 29

US Market Status

Market Closed · Opens in 7h 51m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 2, 2026